Shanghai Huaota Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody shot could tackle stubborn acne Results expected Oct 2026 (estimated)
-
New antibody shot could tackle stubborn acne
Disease control Not yet recruitingThis early-stage trial tests a new drug called HB0043, a bispecific antibody that targets two inflammatory proteins (IL-17A and IL-36R) linked to acne. About 21 adults with moderate to severe facial acne will receive either the drug or a placebo. The main goal is to check safety …
Phase 1/2 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New lung cancer drug HB0025 faces off against standard therapy in major trial
Disease control Not yet recruitingThis Phase 3 trial will test whether a new drug called HB0025, combined with standard chemotherapy, works better than the current treatment tislelizumab plus chemotherapy for people with advanced nonsquamous non-small cell lung cancer. About 500 participants will be randomly assi…
Phase 3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo aims to outperform standard immunotherapy in lung cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether a new experimental drug called HB0025, combined with chemotherapy, works better than the standard immunotherapy pembrolizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer. About 480 participants who have not had p…
Phase 3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC